Viridian Therapeutics (VRDN) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know [Yahoo! Finance]
Viridian Therapeutics (VRDN) had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a "buy" rating on the stock.
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% [Yahoo! Finance]
Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]